Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy

NCT00351871 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: PEG-Intron Plus REBETOL

Sponsor

Louisiana State University Health Sciences Center in New Orleans

Collaborators

[object Object]